Effect of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency.
Acute arterial obstruction in hind limb was experimentally induced by intra-arterial injection of sodium laurate saline solution in mongrel dogs, and the inhibitory action of cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]- 3,4-dihydro-2(1H)-quinolinone, OPC-13013) on ulcer formation was studied. Cilostazol at oral doses of 10 and 30 mg/kg inhibited ulcer development. Cilostazol inhibited decrease in skin temperature in obstructed hindlimbs in a dose-dependent manner. Cilostazol also inhibited increase of plasma aldolase, creatine phosphokinase and glutamic oxalacetic transaminase activities, presumably due to necrosis of the skeletal muscle.
D000818:Animals; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001219:Aspartate Aminotransferases / Q000097:blood; D001393:Azoles / Q000627:therapeutic use*; D000077407:Cilostazol; D003402:Creatine Kinase / Q000097:blood; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005634:Fructose-Bisphosphate Aldolase / Q000097:blood; D008297:Male; D012881:Skin Temperature / Q000187:drug effects; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D001393:Azoles; D005343:Fibrinolytic Agents; D013777:Tetrazoles; D014665:Vasodilator Agents; D001219:Aspartate Aminotransferases; D003402:Creatine Kinase; D005634:Fructose-Bisphosphate Aldolase; D000077407:Cilostazol